Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues:
Total revenues	$ 36	$ 61	$ 121	$ 90
Costs and expenses:
Production costs	204	230	608	676
Research and development	1,102	1,190	3,445	3,214
General and administrative	2,085	1,846	6,070	5,555
Total costs and expenses	3,391	3,266	10,123	9,445
Operating loss	(3,355)	(3,205)	(10,002)	(9,355)
Interest and other income	69	8	131	44
Interest expense and other finance costs	(51)	(193)	(617)	(537)
Extinguishment of notes payable			142	(250)
Convertible note valuation adjustment		(4)		12
Settlement of litigation				260
Redeemable warrants valuation adjustment	31	446	(120)	1,485
Net loss	(3,306)	(2,948)	(10,466)	(8,341)
Other comprehensive income (loss):
Unrealized loss on marketable securities	(75)		(12)
Net comprehensive loss	$ (3,381)	$ (2,948)	$ (10,478)	$ (8,341)
Basic and diluted loss per share	$ (0.08)	$ (1.13)	$ (0.36)	$ (4.41)
Weighted average shares outstanding, basic and diluted	38,907,546	2,603,854	28,826,283	1,891,782
United States [Member]
Revenues:
Clinical treatment programs	$ 27	$ 56	$ 110	$ 60
Europe [Member]
Revenues:
Clinical treatment programs	$ 9	$ 5	$ 11	$ 30